A 52-week, double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of Nintedanib, 150 mg twice daily, in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Boehringer Ingelheim Corporation

Contributors

Morrison, Lake Daniel Principal Investigator

Start/End

April 19, 2017 - March 31, 2020